Azathioprine, cyclophosphamide and chlorambucil
Identifieur interne : 003086 ( Main/Exploration ); précédent : 003085; suivant : 003087Azathioprine, cyclophosphamide and chlorambucil
Auteurs : R. A. Luqmani ; R. G. Palmer ; P. A. BaconSource :
- Bailliere's Clinical Rheumatology [ 0950-3579 ] ; 1990.
English descriptors
- Teeft :
- Abnormality, Alkylating, Alkylating agents, American journal, Annals oflnternal medicine, Arthritis, Azathioprine, Azathioprine group, Bladder, Bladder toxicity, Bolus, British journal, Cell division, Chlorambucil, Chlorambucil therapy, Chromosome, Chromosome damage, Cyclophosphamide, Cyclophosphamide therapy, Cytotoxic, Cytotoxic agents, Cytotoxic drugs, Decker, Dos, England journal, Erythematosus, Granulomatosis, Immune, Immunosuppressive, Immunosuppressive drugs, Intermittent cyclophosphamide, Internal medicine, Intravenous, Intravenous cyclophosphamide, Long term, Lupus, Lupus nephritis, Luqmani, Lymphocyte, Malignancy, Malignant, Methotrexate, Nephritis, Nephrotic syndrome, Nodosa, Placebo, Polyarteritis, Polyarteritis nodosa, Prednisolone, Quarterly journal, Remission, Renal, Renal disease, Renal failure, Renal function, Rheumatic, Rheumatic diseases, Rheumatism, Rheumatoid, Rheumatoid arthritis, Rheumatoid disease, Rheumatoid factor, Rheumatoid vasculitis, Rheumatology, Steroid, Systemic, Systemic lupus erythematosus, Toxic effects, Toxicity, Uveitis, Vasculitis.
Abstract
Summary: Immunosuppressive agents serve a major role in the management of oncefatal conditions such as the systemic necrotizing vasculitides, but they are also being used in more common, chronic inflammatory disorders such as rheumatoid arthritis. The drugs are all capable of reducing cell division but they differ in their modes of action. This is in keeping with their differing rates of action, and different indications. Azathioprine is a valuable alternative to slow-acting antirheumatic drugs in older patients with rheumatoid arthritis. Cyclophosphamide has transformed the outlook of many forms of vasculitis. Chlorambucil is particularly useful in improving the prognosis for children with amyloidosis secondary to juvenile chronic arthritis. We have tried to highlight the role of these drugs in a number of rheumatic diseases. We have emphasized their clinical applications, with some laboratory evidence for their effects. The major side-effects are reviewed. Finally, we have discussed their possible mechanisms of action.
Url:
DOI: 10.1016/S0950-3579(05)80009-3
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001464
- to stream Istex, to step Curation: 001464
- to stream Istex, to step Checkpoint: 001E57
- to stream Main, to step Merge: 003155
- to stream Main, to step Curation: 003086
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Azathioprine, cyclophosphamide and chlorambucil</title><author><name sortKey="Luqmani, R A" sort="Luqmani, R A" uniqKey="Luqmani R" first="R. A." last="Luqmani">R. A. Luqmani</name></author><author><name sortKey="Palmer, R G" sort="Palmer, R G" uniqKey="Palmer R" first="R. G." last="Palmer">R. G. Palmer</name></author><author><name sortKey="Bacon, P A" sort="Bacon, P A" uniqKey="Bacon P" first="P. A." last="Bacon">P. A. Bacon</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:DCA905E82149E9C4F47881CFFA34DDF6DC54C1EE</idno><date when="1990" year="1990">1990</date><idno type="doi">10.1016/S0950-3579(05)80009-3</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-KGW2L89B-V/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001464</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001464</idno><idno type="wicri:Area/Istex/Curation">001464</idno><idno type="wicri:Area/Istex/Checkpoint">001E57</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001E57</idno><idno type="wicri:doubleKey">0950-3579:1990:Luqmani R:azathioprine:cyclophosphamide:and</idno><idno type="wicri:Area/Main/Merge">003155</idno><idno type="wicri:Area/Main/Curation">003086</idno><idno type="wicri:Area/Main/Exploration">003086</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Azathioprine, cyclophosphamide and chlorambucil</title><author><name sortKey="Luqmani, R A" sort="Luqmani, R A" uniqKey="Luqmani R" first="R. A." last="Luqmani">R. A. Luqmani</name></author><author><name sortKey="Palmer, R G" sort="Palmer, R G" uniqKey="Palmer R" first="R. G." last="Palmer">R. G. Palmer</name></author><author><name sortKey="Bacon, P A" sort="Bacon, P A" uniqKey="Bacon P" first="P. A." last="Bacon">P. A. Bacon</name></author></analytic><monogr></monogr><series><title level="j">Bailliere's Clinical Rheumatology</title><title level="j" type="abbrev">BACR</title><idno type="ISSN">0950-3579</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1990">1990</date><biblScope unit="volume">4</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="595">595</biblScope><biblScope unit="page" to="619">619</biblScope></imprint><idno type="ISSN">0950-3579</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0950-3579</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Abnormality</term><term>Alkylating</term><term>Alkylating agents</term><term>American journal</term><term>Annals oflnternal medicine</term><term>Arthritis</term><term>Azathioprine</term><term>Azathioprine group</term><term>Bladder</term><term>Bladder toxicity</term><term>Bolus</term><term>British journal</term><term>Cell division</term><term>Chlorambucil</term><term>Chlorambucil therapy</term><term>Chromosome</term><term>Chromosome damage</term><term>Cyclophosphamide</term><term>Cyclophosphamide therapy</term><term>Cytotoxic</term><term>Cytotoxic agents</term><term>Cytotoxic drugs</term><term>Decker</term><term>Dos</term><term>England journal</term><term>Erythematosus</term><term>Granulomatosis</term><term>Immune</term><term>Immunosuppressive</term><term>Immunosuppressive drugs</term><term>Intermittent cyclophosphamide</term><term>Internal medicine</term><term>Intravenous</term><term>Intravenous cyclophosphamide</term><term>Long term</term><term>Lupus</term><term>Lupus nephritis</term><term>Luqmani</term><term>Lymphocyte</term><term>Malignancy</term><term>Malignant</term><term>Methotrexate</term><term>Nephritis</term><term>Nephrotic syndrome</term><term>Nodosa</term><term>Placebo</term><term>Polyarteritis</term><term>Polyarteritis nodosa</term><term>Prednisolone</term><term>Quarterly journal</term><term>Remission</term><term>Renal</term><term>Renal disease</term><term>Renal failure</term><term>Renal function</term><term>Rheumatic</term><term>Rheumatic diseases</term><term>Rheumatism</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Rheumatoid disease</term><term>Rheumatoid factor</term><term>Rheumatoid vasculitis</term><term>Rheumatology</term><term>Steroid</term><term>Systemic</term><term>Systemic lupus erythematosus</term><term>Toxic effects</term><term>Toxicity</term><term>Uveitis</term><term>Vasculitis</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Summary: Immunosuppressive agents serve a major role in the management of oncefatal conditions such as the systemic necrotizing vasculitides, but they are also being used in more common, chronic inflammatory disorders such as rheumatoid arthritis. The drugs are all capable of reducing cell division but they differ in their modes of action. This is in keeping with their differing rates of action, and different indications. Azathioprine is a valuable alternative to slow-acting antirheumatic drugs in older patients with rheumatoid arthritis. Cyclophosphamide has transformed the outlook of many forms of vasculitis. Chlorambucil is particularly useful in improving the prognosis for children with amyloidosis secondary to juvenile chronic arthritis. We have tried to highlight the role of these drugs in a number of rheumatic diseases. We have emphasized their clinical applications, with some laboratory evidence for their effects. The major side-effects are reviewed. Finally, we have discussed their possible mechanisms of action.</div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Bacon, P A" sort="Bacon, P A" uniqKey="Bacon P" first="P. A." last="Bacon">P. A. Bacon</name><name sortKey="Luqmani, R A" sort="Luqmani, R A" uniqKey="Luqmani R" first="R. A." last="Luqmani">R. A. Luqmani</name><name sortKey="Palmer, R G" sort="Palmer, R G" uniqKey="Palmer R" first="R. G." last="Palmer">R. G. Palmer</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003086 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003086 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:DCA905E82149E9C4F47881CFFA34DDF6DC54C1EE
|texte= Azathioprine, cyclophosphamide and chlorambucil
}}
| This area was generated with Dilib version V0.6.33. |  |